MARKET

TXG

TXG

10X GENOMICS, INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

184.11
-2.89
-1.55%
Closed 17:41 07/29 EDT
OPEN
187.87
PREV CLOSE
187.00
HIGH
189.73
LOW
183.38
VOLUME
386.51K
TURNOVER
--
52 WEEK HIGH
208.99
52 WEEK LOW
92.54
MARKET CAP
20.22B
P/E (TTM)
-36.6017
1D
5D
1M
3M
1Y
5Y
Will 10x Genomics (TXG) Report Negative Earnings Next Week? What You Should Know
10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 1d ago
BRIEF-Bio-Rad And 10X Genomics Announce Settlement To Resolve Multiple Litigations
reuters.com · 2d ago
Bio-Rad and 10x Genomics Announce Settlement to Resolve Multiple Litigations
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Bio-Rad and 10x Genomics, Inc. (Nasdaq: TXG) have reached a final settlement to resolve multiple long-running l...
Business Wire · 2d ago
BRIEF-10X Genomics Inc Says Entered Into A Global Settlement And Cross-License Agreement With Bio-Rad Laboratories, Inc
reuters.com · 2d ago
10x Genomics signs global patent cross license pact with Bio-Rad
10x Genomics (TXG) has entered into a global settlement and cross-license agreement with Bio-Rad Laboratories (BIO).The agreement resolves all outstanding litigation and other proceedings between the two companies across all
Seekingalpha · 2d ago
BRIEF-10X Genomics Signs Global Patent Cross License Agreement With Bio-Rad
reuters.com · 2d ago
10x Genomics Entered Global Settlement And Patent Cross License With Bio-Rad Laboratories Resolving All Outstanding Litigation; Co. To Pay Bio-Rad $29.4M In Royalties And Interest Related To GEM Product Sales
On July 27, 2021, 10x Genomics, Inc. (the “Company”) announced that it entered into a global settlement and patent cross license with Bio-Rad Laboratories, Inc. (“Bio-Rad”) resolving all
Benzinga · 3d ago
Top 5 Trades of the Eaton Vance Worldwide Health Sciences Fund
GuruFocus News · 3d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TXG. Analyze the recent business situations of 10X GENOMICS, INC. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TXG stock price target is 205.89 with a high estimate of 240.00 and a low estimate of 175.00.
EPS
Institutional Holdings
Institutions: 363
Institutional Holdings: 77.80M
% Owned: 70.86%
Shares Outstanding: 109.80M
TypeInstitutionsShares
Increased
127
10.17M
New
75
7.49M
Decreased
85
6.97M
Sold Out
60
1.45M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+0.52%
Healthcare Equipment & Supplies
+0.72%
Key Executives
Non-Executive Chairman/Independent Director
John Stuelpnagel
President/Co-Founder/Chief Scientific Officer/Director
Benjamin Hindson
Chief Executive Officer/Co-Founder/Director
Serge Saxonov
Chief Financial Officer
Justin McAnear
Chief Human Resource Officer
Jean Philibert
General Counsel
Eric Whitaker
Other
Bradford Crutchfield
Other
Ruth De Backer
Independent Director
Sridhar Kosaraju
Independent Director
Mathai Mammen
Independent Director
Kimberly Popovits
Independent Director
Bryan Roberts
Independent Director
Shehnaaz Suliman
No Data
About TXG
10x Genomics, Inc. is a life science technology company. The Company’s integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. The Company’s product consists of chromium single cell gene expression solution, cell immune profiling solution, cell copy number variation (CNV) solution, Cell assay for transposase accessible chromatin (ATAC) solution. The Company’s Chromium platform enables analysis of individual biological components, such as up to millions of single cells. Its Visium platform is designed to identify where biological components are located and how they are arranged with respect to each other. Its molecular assays are used with its Chromium platform, and with its planned Visium platform, to provide sensitive and robust biochemistries that convert minute amounts of biological analytes into detectable signals.

Webull offers kinds of 10X Genomics Inc stock information, including NASDAQ:TXG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TXG stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TXG stock methods without spending real money on the virtual paper trading platform.